{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:55:07Z","timestamp":1781585707674,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the efficacy and safety of low-dose rituximab (RTX, 100 mg\/month) versus belimumab (BEL, 10 mg\/kg), as a control, in the treatment of systemic lupus erythematosus (SLE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 117 SLE patients who received low-dose RTX (n=51) or BEL (n=66) at Fujian Medical University Union Hospital between January 2020 and June 2023. Data on baseline characteristics, laboratory parameters (platelet count, creatinine, proteinuria, complement C3\/C4, erythrocyte sedimentation rate (ESR)), disease activity (SLEDAI\u22122K), glucocorticoid dosage, concomitant immunosuppressant use, efficacy assessments, and adverse events were collected. Paired t-tests or Wilcoxon tests were used for within-group comparisons, and independent-sample t-tests or Mann-Whitney U tests for between-group comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No significant differences were observed between the two groups at baseline for SLEDAI-2K, glucocorticoid levels, or anti-dsDNA (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05). After treatment, both groups showed significant improvements in SLEDAI-2K, dsDNA levels, and glucocorticoid dosage (all\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05), with a greater reduction in glucocorticoid dosage in the BEL group (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02). Both treatments increased complement C3\/C4 and decreased immunoglobulins (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05), with no significant between-group differences. Low-dose RTX achieved a overall efficacy of 39.2% versus 57.6% for BEL. Both agents increased platelet count, improved hypoalbuminemia and hypercoagulability, and decreased ESR; BEL was superior in reducing D-dimer (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.03). In renal outcomes, both reduced proteinuria equivalently; BEL improved creatinine while RTX caused a small but clinically acceptable rise in creatinine. Adverse events occurred in 12.12% (BEL) and 7.8% (RTX) of patients, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05), with no unexpected safety signals. Concomitant immunosuppressant use also varied between groups, with mycophenolate mofetil (MMF) more common in BEL and Cyclosporine A (CsA) in RTX.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low-dose RTX (100 mg\/month) can be regarded as a treatment option for SLE, based on its comparable efficacy to BEL in improving disease activity, increasing platelet count, and ameliorating proteinuria. Although BEL shows greater advantages in reducing glucocorticoid dosage and improving hypercoagulability, the overall evidence supports low-dose RTX as an effective and safe alternative for SLE, with a favourable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1806879","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:26:51Z","timestamp":1781584011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of low dose of rituximab to treat systemic lupus erythematosus"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fuzhou First General Hospital Affiliated with Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhong","family":"Que","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fuzhou First General Hospital Affiliated with Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076578","article-title":"Advances in the pathogenesis and treatment of systemic lupus erythematosus","volume":"24","author":"Accapezzato","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102864","article-title":"Pregnancy-related complications in systemic lupus erythematosus","volume":"132","author":"Tan","year":"2022","journal-title":"J Autoimmun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J Autoimmun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.826152","article-title":"Rituximab in systemic lupus erythematosus: transient effects on autoimmunity associated lymphocyte phenotypes and implications for immunogenicity","volume":"13","author":"Faustini","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmct1207259","article-title":"Belimumab for systemic lupus erythematosus","volume":"368","author":"Hahn","year":"2013","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead253","article-title":"Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials","volume":"63","author":"Gomez","year":"2024","journal-title":"Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032569","article-title":"Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial","volume":"9","author":"Jones","year":"2019","journal-title":"BMJ Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2020.03.002","article-title":"2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"59","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(23)00091-7","article-title":"Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study","volume":"5","author":"Rodziewicz","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04668-4","article-title":"Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus","volume":"40","author":"Ilizaliturri-Guerra","year":"2020","journal-title":"Rheumatol Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211048643","article-title":"A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus","volume":"12","author":"Zhang","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-298X.2022.02.001","article-title":"Ultra-low dose rituximab regimen for treatment of lupus nephritis: an observational study","volume":"31","author":"Chen","year":"2022","journal-title":"Chin J Nephrol Dialysis Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-298X.2022.05.001","article-title":"Reduced dose rituximab for refractory lupus nephritis: a preliminary observational study","volume":"31","author":"Chen","year":"2022","journal-title":"Chin J Nephrol Dialysis Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.09.009","article-title":"EULAR\/ACR classification criteria for SLE","volume":"49","author":"Aringer","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B24","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","volume-title":"National Cancer Institute","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: What have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2020-0009","article-title":"2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"1","author":"Li","year":"2020","journal-title":"Rheumatol Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14997","article-title":"Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia","volume":"27","author":"Suh","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1480915","article-title":"Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tanaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103837","article-title":"Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumab","volume":"24","author":"Frade-Sosa","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2019.1696644","article-title":"Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab","volume":"42","author":"Abe","year":"2019","journal-title":"Immunol Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.207","article-title":"Pos0851 rituximab in refractory lupus nephritis: efficacy and safety data from single center cohort","volume":"84","author":"Uludag","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.1851","article-title":"Abs0486 comparative analysis of belimumab, anifrolumab, and rituximab in systemic lupus erythematosus: a retrospective study of clinical and analytical outcomes","volume":"84","author":"Calabuig","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2026.103987","article-title":"Risk of infection for different B-cell targeting agents in treating systemic lupus erythematosus: A systematic review and network meta-analysis","volume":"25","author":"Yu","year":"2026","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40719","article-title":"The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review","volume":"15","author":"Abid","year":"2023","journal-title":"Cureus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:26:54Z","timestamp":1781584014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1806879"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1806879","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1806879"}}